Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.
Hsieh MH, Fang YF, Chang WC, Kuo HP, Lin SY, Liu HP, Liu CL, Chen HC, Ku YC, Chen YT, Chang YH, Chen YT, Hsi BL, Tsai SF, Huang SF. Hsieh MH, et al. Among authors: fang yf. Lung Cancer. 2006 Sep;53(3):311-22. doi: 10.1016/j.lungcan.2006.06.005. Epub 2006 Jul 25. Lung Cancer. 2006. PMID: 16870303
Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
Chang JW, Liu HP, Hsieh MH, Fang YF, Hsieh MS, Hsieh JJ, Chiu YT, Tsai HY, Chen YH, Chen YT, Hsu HY, Chen YT, Tsai SF, Chen YR, Hsi BL, Huang SF. Chang JW, et al. Among authors: fang yf. Lung Cancer. 2008 Sep;61(3):328-39. doi: 10.1016/j.lungcan.2008.01.009. Epub 2008 Mar 4. Lung Cancer. 2008. PMID: 18304690
The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations.
Liu CY, Wang CL, Li SH, Hsu PC, Chen CH, Lin TY, Kuo CH, Fang YF, Ko HW, Yu CT, Yang TY, Yang CT. Liu CY, et al. Among authors: fang yf. Oncotarget. 2017 Jun 27;8(57):97602-97612. doi: 10.18632/oncotarget.18746. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228636 Free PMC article.
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer.
Huang AC, Huang CH, Ju JS, Chiu TH, Tung PH, Wang CC, Liu CY, Chung FT, Fang YF, Guo YK, Kuo CS, Yang CT. Huang AC, et al. Among authors: fang yf. Ther Adv Med Oncol. 2021 Jul 31;13:17588359211035710. doi: 10.1177/17588359211035710. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34377157 Free PMC article.
182 results